<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02324049</url>
  </required_header>
  <id_info>
    <org_study_id>NGLU-CL02</org_study_id>
    <nct_id>NCT02324049</nct_id>
  </id_info>
  <brief_title>Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 in MPS IIIB</brief_title>
  <official_title>A Phase I/II Open Label Study in MPS IIIB Subjects to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 Administered Intravenously</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexion Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alexion Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and tolerability of intravenous (IV) administration of SBC 103 in
      subjects with mucopolysaccharidosis III, type B (MPS IIIB, Sanfilippo B) with evaluable signs
      or symptoms of developmental delay.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>December 2014</start_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability of IV SBC-103 as measured by Physical examination, vital signs, ECG, clinical laboratory tests, concomitant medication and development of anti-drug antibodies.</measure>
    <time_frame>Baseline to Week 156</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK/PD Effect of SBC-103 after single and multiple doses, neurocognitive and developmental function, brain structure volumetric assessment, and indices of microstructural integrity.</measure>
    <time_frame>Baseline to Week 156</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">9</enrollment>
  <condition>Mucopolysaccharidosis IIIB</condition>
  <arm_group>
    <arm_group_label>SBC-103</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>There are three parts to the study, for part A and B patients will be enrolled into one of three doses, then in part C randomized into one of the two different higher doses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SBC-103</intervention_name>
    <arm_group_label>SBC-103</arm_group_label>
    <other_name>recombinant human alpha-N-acetylglucosaminidase (rhNAGLU)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Patient will be greater than or equal to 2 years of age but less than 12 years of age
             at the time of informed consent.

          -  Definitive diagnosis of MPS IIIB.

          -  Documented developmental delay

        Key Exclusion Criteria:

          -  Received treatment with gene therapy at any time

          -  Previous hematopoietic stem cell or bone marrow transplant.

          -  Has any internal or non-removable external metal items that may present a safety risk
             for study assessments that utilize magnetic fields, or any other medical condition or
             circumstance in which an MRI is contraindicated according to local institutional
             policy.

          -  Known hypersensitivity to eggs.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 15, 2014</study_first_submitted>
  <study_first_submitted_qc>December 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2014</study_first_posted>
  <last_update_submitted>October 9, 2017</last_update_submitted>
  <last_update_submitted_qc>October 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MPS IIIB</keyword>
  <keyword>Mucopolysaccharidosis</keyword>
  <keyword>Mucopolysaccharidosis type IIIB</keyword>
  <keyword>Sanfilippo Syndrome</keyword>
  <keyword>Metabolism, Inborn Errors</keyword>
  <keyword>Metabolic Diseases</keyword>
  <keyword>Genetic Diseases, Inborn</keyword>
  <keyword>Carbohydrate Metabolism, Inborn Errors</keyword>
  <keyword>Connective Tissue Diseases</keyword>
  <keyword>Lysosomal Storage Diseases</keyword>
  <keyword>Mucinoses</keyword>
  <keyword>Mucopolysaccharidoses</keyword>
  <keyword>Pathologic Processes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mucopolysaccharidoses</mesh_term>
    <mesh_term>Mucopolysaccharidosis III</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

